Cancer Research and Treatment

S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion

Sabrina Groß, Michael Bitzer, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho

Zeitschrift für Gastroenterologie.2024; 62(01): 73. CrossRef

S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0

Michael Bitzer, Sabrina Groß, Jörg Albert, Susanne Blödt, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Markus Follmann, Paul Freudenberger, Cihan Gani, Andreas Geier, Eleni Gkika, Martin Götz, Tho

Zeitschrift für Gastroenterologie.2024; 62(01): e67. CrossRef

Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone

Masaaki Kagoura, Shin Kobayashi, Motohiro Kojima, Masashi Kudo, Motokazu Sugimoto, Masaru Konishi, Naoto Gotohda

European Journal of Surgical Oncology.2024; 50(3): 107980. CrossRef

S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0

Zeitschrift für Gastroenterologie.2024; 62(02): e213. CrossRef

S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion

Zeitschrift für Gastroenterologie.2024; 62(02): 231. CrossRef

Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer

Tian-mei Zeng, Guang Yang, Cheng Lou, Wei Wei, Chen-jie Tao, Xi-yun Chen, Qin Han, Zhuo Cheng, Pei-pei Shang, Yu-long Dong, He-ming Xu, Lie-ping Guo, Dong-sheng Chen, Yun-jie Song, Chuang Qi, Wang-long Deng, Zhen-gang Yuan

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion

Michael Bitzer, Sabrina Groß, Jörg Albert, Judit Boda-Heggemann, Thomas Brunner, Reiner Caspari, Enrico De Toni, Frank Dombrowski, Matthias Evert, Andreas Geier, Eleni Gkika, Martin Götz, Thomas Helmberger, Ralf-Thorsten Hoffmann, Peter Huppert, Achim Kau

Zeitschrift für Gastroenterologie.2023; 61(04): e92. CrossRef

S3-Leitlinie Diagnostik und Therapie biliärer Karzinome

Zeitschrift für Gastroenterologie.2023; 61(04): 420. CrossRef

Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer

Anti-Cancer Activity of Verteporfin in Cholangiocarcinoma

Jihye L. Golino, Xin Wang, Jing Bian, Benjamin Ruf, Michael Kelly, Baktiar O. Karim, Maggie C. Cam, Changqing Xie

Very rare metastatic phenomena of biliary tract cancer to the cerebellum: A case report and review of the literature

International Journal of Surgery Case Reports.2023; 111: 108819. CrossRef

Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population

Tiantian Wu, Changsheng Pu, Qiang Wang, Keming Zhang

Effectivity of Palliative Care Bundle on Advanced Gallbladder Cancer: A Randomised Controlled Trial

Kusum K. Rohilla, C. Vasantha Kalyani, Amit Gupta, Manoj Gupta, Nirmal Matella

Indian Journal of Palliative Care.2023; 29: 447. CrossRef

Response of cholangiocarcinoma with epigastric metastasis to lenvatinib plus sintilimab: A case report and review of literature

World Journal of Gastrointestinal Oncology.2023; 15(11): 2033. CrossRef

S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome

M. Bitzer, S. Voesch, J. Albert, P. Bartenstein, W. Bechstein, S. Blödt, T. Brunner, F. Dombrowski, M. Evert, M. Follmann, C. La Fougère, P. Freudenberger, A. Geier, E. Gkika, M. Götz, E. Hammes, T. Helmberger, R. T. Hoffmann, W. P. Hofmann, P. Huppert, A

Zeitschrift für Gastroenterologie.2022; 60(02): e186. CrossRef

S3-Leitlinie: Diagnostik und Therapie biliärer Karzinome

Zeitschrift für Gastroenterologie.2022; 60(02): 219. CrossRef

Verteporfin synergizes the efficacy of anti-PD-1 in cholangiocarcinoma

Jianyang Fu, Nicole A McGrath, Jihye Lee, Xin Wang, Gagandeep Brar, Changqing Xie

Hepatobiliary & Pancreatic Diseases International.2022; 21(5): 485. CrossRef

Cytotoxic activities of ethanolic crude extracts from fruiting bodies of bamboo mushrooms (Dictyophora spp.) against cholangiocarcinoma cells

Pathanin Chantree, Sirilak Chumkiew, Mantana Jamklang, Pongsakorn Martviset

Research Results in Pharmacology.2022; 8(1): 33. CrossRef

LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation

Eunsil Sung, Minkyung Ko, Ju-young Won, Yunju Jo, Eunyoung Park, Hyunjoo Kim, Eunji Choi, Ui-jung Jung, Jaehyoung Jeon, Youngkwang Kim, Hyejin Ahn, Da-som Choi, Seunghyun Choi, Youngeun Hong, Hyeyoung Park, Hanbyul Lee, Yong-Gyu Son, Kyeongsu Park, Jonghw

Wei Li, Yueqi Wang, Yiyi Yu, Qian Li, Yan Wang, Chenlu Zhang, Xiaojing Xu, Xi Guo, Yu Dong, Yuehong Cui, Qing Hao, Lujia Huang, Houbao Liu, Tianshu Liu

Selective Internal Radiation Therapy with Yttrium-90 for Intrahepatic Cholangiocarcinoma: A Systematic Review on Post-Treatment Dosimetry and Concomitant Chemotherapy

Sedighe Hosseini Shabanan, Nariman Nezami, Mohamed E. Abdelsalam, Rahul Anil Sheth, Bruno C. Odisio, Armeen Mahvash, Peiman Habibollahi

Can patients with gallbladder adenocarcinoma and liver metastases obtain survival benefit from surgery? A population-based study

Tianming Gao, Hua Tang, Baohuan Zhou, Dousheng Bai, Shengjie Jin, Chi Zhang, Guoqing Jiang

Pharmacophore Based Design of Probable FGFR-1 Inhibitors from the 3D Crystal Structure of Infigratinib - A Drug Used in the Treatment of Cholangiocarcinomas

Koushik Sarker , Avijit Ghosh , Abhijit Saha, Suvasish Mishra, Subrata Sen

Letters in Drug Design & Discovery.2022; 19(4): 314. CrossRef

Cannabidiol and Cannabigerol Inhibit Cholangiocarcinoma Growth In Vitro via Divergent Cell Death Pathways

Michael J. Viereckl, Kelsey Krutsinger, Aaron Apawu, Jian Gu, Bryana Cardona, Donovan Barratt, Yuyan Han

Idiopathic hyperammonemic encephalopathy secondary to gemcitabine–cisplatin treatment

Karlijn Verkerk, Hans-Martin Otten, Alwin D. R. Huitema

Cancer Chemotherapy and Pharmacology.2022; 90(5): 417. CrossRef

Enhanced gemcitabine cytotoxicity with knockdown of multidrug resistance protein genes in human cholangiocarcinoma cell lines

Jiaqi Yang, David Sontag, Yuewen Gong, Gerald Y Minuk

Journal of Gastroenterology and Hepatology.2021; 36(4): 1103. CrossRef

Juan W Valle, R Katie Kelley, Bruno Nervi, Do-Youn Oh, Andrew X Zhu

Current Status and Future Perspectives of Perioperative Therapy for Resectable Biliary Tract Cancer: A Multidisciplinary Review

Changhoon Yoo, Sang Hyun Shin, Joon-Oh Park, Kyu-Pyo Kim, Jae Ho Jeong, Baek-Yeol Ryoo, Woohyung Lee, Ki-Byung Song, Dae-Wook Hwang, Jin-hong Park, Jae Hoon Lee

Thoracoscopic metastasectomy is the method of choice in the stepwise treatment of disseminated cholangiocellular carcinoma

A.A. Pechetov, A.V. Chzhao, Sh.V. Ragimov, D.A. Volchansky, M.A. Makov, B.N. Gurmikov

Onkologiya. Zhurnal imeni P.A.Gertsena.2021; 10(2): 39. CrossRef

IGF2BP1 IS A POOR PROGNOSTIC FACTOR IN EXTRAHEPATIC CHOLANGIOCARCINOMA

INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 80. CrossRef

Efficacy and Safety of Gemcitabine Plus Cisplatin as Potential Preoperative Chemotherapy in Locally Advanced Intrahepatic, Perihilar, and Mid-Cholangiocarcinoma

Lynn E. Nooijen, Lotte C. Franken, Ali Belkouz, Ikrame Oulad Abdennabi, Marc G. Besselink, Olivier R. Busch, Rutger-Jan Swijnenburg, Heinz-Josef Klümpen, Joris I. Erdmann

American Journal of Clinical Oncology.2021; 44(10): 526. CrossRef

Novel biomarkers for cholangiocarcinoma: how can it enhance diagnosis, prognostication, and investigational drugs? Part-1

Ranu S Sinniah, Mark S Shapses, Mohammad Umar Ahmed, Hani Babiker, Sreenivasa R. Chandana

Expert Opinion on Investigational Drugs.2021; 30(10): 1047. CrossRef

RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin

Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo

Journal of Clinical Medicine.2021; 10(20): 4652. CrossRef

Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR

Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef

Lenvatinib Plus PD-1 Inhibitors as First-Line Treatment in Patients With Unresectable Biliary Tract Cancer: A Single-Arm, Open-Label, Phase II Study

Qiyi Zhang, Xingyu Liu, Shumei Wei, Lufei Zhang, Yang Tian, Zhenzhen Gao, Ming Jin, Sheng Yan

Biliäre Karzinome: Zielstrukturen für eine molekulare Systemtherapie

Deutsches Ärzteblatt Online.2021;[Epub] CrossRef

Treatment of advanced gallbladder cancer: A SEER‐based study

Weipu Mao, Fang Deng, Dongyan Wang, Li Gao, Xiuquan Shi

LINC01714 Enhances Gemcitabine Sensitivity by Modulating FOXO3 Phosphorylation in Cholangiocarcinoma

Sheng Shen, Jiwen Wang, Bohao Zheng, Ying Tao, Min Li, Yueqi Wang, Xiaoling Ni, Tao Suo, Houbao Liu, Han Liu, Jiwei Zhang

Molecular Therapy - Nucleic Acids.2020; 19: 446. CrossRef

Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers

Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai

World Journal of Gastrointestinal Oncology.2020; 12(1): 83. CrossRef

Low immune index correlates with favorable prognosis but with reduced benefit from chemotherapy in gallbladder cancer

Jie Wang, Xiaobo Bo, Changcheng Wang, Yanlei Xin, Lingxi Nan, Rongkui Luo, Lingli Chen, Xiao Shi, Tao Suo, Xiaoling Ni, Han Liu, Sheng Shen, Min Li, Pinxiang Lu, Yueqi Wang, Houbao Liu

Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers

Jonathan D Mizrahi, Valerie Gunchick, Kabir Mody, Lianchun Xiao, Phanikeerthi Surapaneni, Rachna T Shroff, Vaibhav Sahai

World Journal of Gastrointestinal Oncology.2020; 12(1): 83. CrossRef

Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer

Mansi Arora, James M. Bogenberger, Amro Abdelrahman, Jennifer L. Leiting, Xianfeng Chen, Jan B. Egan, Aradhana Kasimsetty, Elzbieta Lenkiewicz, Smriti Malasi, Pedro Luiz Serrano Uson, Bolni Marius Nagalo, Yumei Zhou, Marcela A. Salomao, Heidi E. Kosiorek,

Cancer Chemotherapy and Pharmacology.2020; 85(6): 1063. CrossRef

NUC-1031 in biliary tract cancer: from bench to bedside and back?

Lenka N. C. Boyd, Godefridus J. Peters, Geert Kazemier, Elisa Giovannetti

Cancer Chemotherapy and Pharmacology.2020; 85(6): 1011. CrossRef

Targeting cancer stem cells in cholangiocarcinoma (Review)

Nicole Mcgrath, Jianyang Fu, Sophie Gu, Changqing Xie

International Journal of Oncology.2020; 57(2): 397. CrossRef

Phase 2 study of lenvatinib monotherapy as second-line treatment in unresectable biliary tract cancer: primary analysis results

Makoto Ueno, Masafumi Ikeda, Takashi Sasaki, Fumio Nagashima, Nobumasa Mizuno, Satoshi Shimizu, Hiroki Ikezawa, Nozomi Hayata, Ryo Nakajima, Chigusa Morizane

Combined treatment for locally advanced cholangiocellular liver cancer - the case report

A. N. Polyakov, Yu. I. Patyutko, A. Yu. Syskova, K. A. Romanova, I. S. Bazin, O. N. Sergeeva, E. R. Virshke, E. S. Makarov, E. Yu. Antonova, A. A. Kirshin, D. V. Podluzhnyi

Research and Practical Medicine Journal.2019; 6(4): 158. CrossRef

Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin

J. Dierks, M. P. Gaspersz, A. Belkouz, J. L. A. van Vugt, R. J. S. Coelen, J. W. B. de Groot, A. J. ten Tije, W. G. Meijer, J. F. M. Pruijt, T. van Voorthuizen, D. J. van Spronsen, M. Rentinck, D. ten Oever, J. M. Smit, H. M. Otten, T. M. van Gulik, J. W.

Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy

Jae Woo Lee, Yong-Tae Kim, Sang Hyub Lee, Jun Hyuk Son, Jin Woo Kang, Ji Kon Ryu, Dong Kee Jang, Woo Hyun Paik, Ban Seok Lee

Tumor-infiltrating mast cells predict prognosis and gemcitabine-based adjuvant chemotherapeutic benefit in biliary tract cancer patients

Xiaobo Bo, Jie Wang, Tao Suo, Xiaoling Ni, Han Liu, Sheng Shen, Min Li, Yueqi Wang, Houbao Liu, Jiejie Xu

Revision of bilateral self-expandable metallic stents placed using the stent-in-stent technique for malignant hilar biliary obstruction

Jun Hyuk Son, Hee Seung Lee, Sang Hyub Lee, Seungmin Bang, Jinwoo Kang, Woo Hyun Paik, Ji Kon Ryu, Yong-Tae Kim

Hepatobiliary & Pancreatic Diseases International.2018; 17(5): 437. CrossRef

Aktueller Therapiealgorithmus des intrahepatischen cholangiozellulären Karzinoms

G. Lurje, J. Bednarsch, C. Roderburg, C. Trautwein, U. P. Neumann

Defining the Chance of Statistical Cure Among Patients with Extrahepatic Biliary Tract Cancer

Gaya Spolverato, Fabio Bagante, Cecilia G. Ethun, George Poultsides, Thuy Tran, Kamran Idrees, Chelsea A. Isom, Ryan C. Fields, Bradley Krasnick, Emily Winslow, Clifford Cho, Robert C. G. Martin, Charles R. Scoggins, Perry Shen, Harveshp D. Mogal, Carl Sc

World Journal of Surgery.2017; 41(1): 224. CrossRef

Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study

Tulay Kus, Gokmen Aktas, Mehmet Emin Kalender, Alper Sevinc, Celaletdin Camci

Journal of Gastrointestinal Cancer.2017; 48(2): 170. CrossRef

SVCT-2 determines the sensitivity to ascorbate-induced cell death in cholangiocarcinoma cell lines and patient derived xenografts

Changzheng Wang, Hongwei Lv, Wen Yang, Ting Li, Tian Fang, Guishuai Lv, Qin Han, Liwei Dong, Tianyi Jiang, Beige Jiang, Guangshun Yang, Hongyang Wang

Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer

Yoshiki Hirooka, Takuya Ishikawa, Hiroki Kawashima, Eizaburo Ohno, Koji Nonogaki, Akira Kanamori, Takanori Hirai, Hiroki Uchida, Osamu Shirai, Hideki Ishikawa, Hidemi Goto

Cancer Chemotherapy and Pharmacology.2017; 80(1): 119. CrossRef

CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy

Dae-Won Lee, Seock-Ah Im, Yu Jung Kim, Yaewon Yang, Jiyoung Rhee, Im Il Na, Kyung-Hun Lee, Tae-Yong Kim, Sae-Won Han, In Sil Choi, Do-Youn Oh, Jee Hyun Kim, Tae-You Kim, Yung-Jue Bang

Cancer Research and Treatment.2017; 49(3): 807. CrossRef

Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients

Bum Jun Kim, Jaewon Hyung, Changhoon Yoo, Kyu-pyo Kim, Seong-Joon Park, Sang Soo Lee, Do Hyun Park, Tae Jun Song, Dong Wan Seo, Sung Koo Lee, Myung-Hwan Kim, Jin-hong Park, Hyungwoo Cho, Baek-Yeol Ryoo, Heung-Moon Chang

Cancer Chemotherapy and Pharmacology.2017; 80(1): 209. CrossRef

Cholangiocarcinoma and its mimickers in primary sclerosing cholangitis

Jonghun John Lee, Sebastian T Schindera, Hyun-Jung Jang, Scott Fung, Tae Kyoung Kim

Impact of radiation dose in postoperative radiotherapy after R1 resection for extrahepatic bile duct cancer: long term results from a single institution

Byoung Hyuck Kim, Eui Kyu Chie, Kyubo Kim, Jin-Young Jang, Sun Whe Kim, Do-Youn Oh, Yung-Jue Bang, Sung W. Ha

The efficacy and safety of different pharmacological interventions for patients with advanced biliary tract cancer: A network meta-analysis

Xin-Fang Sun, Zhi-Kuan He, Jin-Ping Sun, Quan-Xing Ge, Er-Dong Shen

Gemcitabine and cisplatin in inoperable, loco-regionally advanced and metastatic gallbladder cancer: A study from Northern India cancer institute

Vineet Talwar, Shubhra Raina, Varun Goel, Dinesh C. Doval

International Journal of Hepatobiliary and Pancreatic Diseases.2017; 7(2): 1. CrossRef

Expression levels of ROS1/ALK/c-MET and therapeutic efficacy of cetuximab plus chemotherapy in advanced biliary tract cancer

Nai-Jung Chiang, Chiun Hsu, Jen-Shi Chen, Hsiao-Hui Tsou, Ying-Ying Shen, Yee Chao, Ming-Huang Chen, Ta-Sen Yeh, Yan-Shen Shan, Shiu-Feng Huang, Li-Tzong Chen

Chemotherapy for advanced biliary tract carcinoma

Molecular and Clinical Oncology.2016; 5(1): 7. CrossRef